Imaging biomarkers in corticobasal syndrome
Neuroinflammation, White Matter Integrity, AD Biomarkers and Pathology in Corticobasal Syndrome
We will use brain imaging and blood tests to see if inflammation is linked to white-matter damage in people with corticobasal syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT07000851 on ClinicalTrials.gov |
What this trial studies
Corticobasal syndrome is a neurodegenerative disorder marked by asymmetric motor symptoms and cognitive and behavioral changes. This observational project tests whether neuroinflammation and white-matter microstructure changes are related in people with CBS using PET, advanced MRI, and blood biomarkers. Investigators will use the PET ligand 11C-ER176 to map inflammation, NODDI diffusion imaging to measure white-matter microstructure, and plasma measures such as neurofilament light and GFAP alongside A and tau PET to subgroup patients. Results will be compared to typical amnestic AD cases and healthy controls, and molecular pathology data will be used where available.
Who should consider this trial
Good fit: Adults (18+) who meet possible or probable corticobasal syndrome criteria, can undergo MRI and PET scanning, are not pregnant, are not taking daily anti-inflammatory or recent immunosuppressive therapy, and do not have a progranulin mutation are ideal candidates.
Not a fit: People with MRI contraindications, active generalized inflammatory conditions, recent anti-inflammatory or immunosuppressive treatment, prior anti-amyloid therapy, or progranulin mutations may not receive benefit from this imaging-focused study.
Why it matters
Potential benefit: If successful, the work could identify inflammatory and white-matter biomarkers that improve diagnosis and help target treatments for subgroups of CBS patients.
How similar studies have performed: Related PET inflammation imaging, diffusion MRI (NODDI), and plasma biomarker approaches have provided useful insights in Alzheimer's disease and other tauopathies, although applying 11C-ER176 specifically in CBS is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Meet possible or probable CBS criteria Exclusion Criteria: * Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc) * Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome * Subjects will be excluded if they have a mutation in the progranulin gene * Subjects will excluded if they have received anti-Aβ therapy * Women who are pregnant will be excluded * Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc) * Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning
Where this trial is running
Rochester, Minnesota
- Mayo Clinic — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Jennifer Whitwell, Ph.D. — Mayo Clinic
- Study coordinator: Megan J Meyer, M.B.A.
- Email: meyer.megan6@mayo.edu
- Phone: 507-293-1164
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.